Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Needham Trims COR to 'Buy'

Needham downgraded COR Therapeutics (CORR) to buy from strong buy.

Analyst Mark Monane also cut his $0.37 2001 EPS estimate to $0.34, and cut his target to $42-$44. He says he is disappointed, noting the firm is profitable for the first time in Q4 but the curse of profitability is the need to maintain it. He says the short term is clouded by how much COR can grow this year, especially in Europe where sales are disappointing.

Monane says the good news is that the fundamentals are quite strong, and that COR is an excellent core holding in technology. He says COR's drug is No. 1 in its class in terms of patient share. He notes the drug is used in treating unstable angina, which is the No. 1 reason for hospitalization in the U.S.

blog comments powered by Disqus